https://doi.org/10.4081/monaldi.2023.2766
Impact of percutaneous coronary intervention on renal function in patients with coronary heart disease
Submitted: September 3, 2023
Accepted: October 14, 2023
Published: November 2, 2023
Accepted: October 14, 2023
Abstract Views: 735
PDF: 31
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The relationship between cardiac and renal function is complicated. The impact of percutaneous coronary intervention (PCI) on renal function in patients with coronary artery disease is still unclear. The current study sought to assess renal function change, including the time course of renal function, after elective PCI in patients with improved renal function (IRF) and to identify renal function predictors of major adverse cardiovascular events (MACE). We examined data from 1572 coronary heart disease patients who had coronary angiography (CAG) or PCI in this retrospective cohort study. Patients receiving elective PCI (n=1240) and CAG (n=332) between January 2013 and December 2018 were included. Pre-PCI and procedural variables associated with post-PCI estimated glomerular filtration rate (eGFR), change in renal function after post-PCI follow-up, and post-PCI eGFR association with MACE were investigated. Following the procedure, 88.7% of PCI group patients had unchanged IRF. The treatment of PCI was found to independently correlate with IRF following CAG in an analysis of patients undergoing PCI [odds ratio 4.561 (95% confidence interval: 2.556-8.139); p<0.001]. The area under the receiver operating characteristic curve is 0.763 (model with the treatment of PCI). IRF and stable renal function were both associated with a lower risk of a MACE.
Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute renal injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv 2014;7:1-9.
Watabe H, Sato A, Hoshi T, et al. Association of contrast-induced acute renal injury with long-term cardiovascular events in acute coronary syndrome patients with chronic renal disease undergoing emergent percutaneous coronary intervention. Int J Cardiol 2014;174:57-63.
Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;69:S11-5.
Kai T, Oka S, Hoshino K, et al. Renal dysfunction as a predictor of slow-flow/no-reflow phenomenon and impaired ST segment resolution after percutaneous coronary intervention in ST-elevation myocardial infarction with initial thrombolysis in myocardial infarction grade 0. Circ J 2021;85:1770-8.
Marenzi G, Cabiati A, Cosentino N, et al. Prognostic significance of serum creatinine and its change patterns in patients with acute coronary syndromes. Am Heart J 2015;169:363-70.
Shacham Y, Leshem-Rubinow E, Gal-Oz A, et al. Relation of in-hospital serum creatinine change patterns and outcomes among ST segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Clin Cardiol 2015;38:274–9.
Uemura Y, Ishikawa S, Takemoto K, et al. Improved renal function after percutaneous coronary intervention in non-dialysis patients with acute coronary syndrome and advanced renal dysfunction. Cardiovasc Revasc Med 2021;24:26-30.
Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840-78.
Scirica BM, Mosenzon O, Bhatt DL, et al. Cardiovascular outcomes according to urinary albumin and renal disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. JAMA Cardiol 2018;3:155-63.
Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145-50.
Levey S, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014;311:2518-31.
Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
Brown JR, Solomon RJ, Robey RB, et al. Chronic renal disease progression and cardiovascular outcomes following cardiac catheterization-a population-controlled study. J Am Heart Assoc 2016;5:e003812.
Otsuka K, Shimada K, Katayama H, et al. Prognostic significance of renal dysfunction and its c9ange pattern on outcomes in patients with acute coronary syndrome treated with emergent percutaneous coronary intervention. Heart Vessels 2019;34:735-44.
Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute renal injury in patients undergoing percutaneous coronary interventions.
Okabe T, Yakushiji T, Kido T, et al. Relationship between worsening renal function and long-term cardiovascular mortality in heart failure patients. Int J Cardiol 2017;230:47-52.
Weingart C, Wirnsberger GH. Clinical implications of the estimated glomerular filtration rate. Z Gerontol Geriatr 2021;54:205-10.
Dilsizian V, Gewirtz H, Marwick TH, et al. Cardiac imaging for coronary heart disease risk stratification in chronic renal disease. JACC Cardiovasc Imaging 2021;14:669-82.
DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.
Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 2018;138:1904-7.
Abrass CK Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004;24:46-53.
Hattori M, Nikotic-Paterson DJ, Miyazaki K, et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 1999;71:S47–S50.
Shuvy M, Chen S, Vorobeichik D, et al. Temporal trends in management and outcomes of patients with acute coronary syndrome according to renal function. Int J Cardiol 2017;232:48-52.
Bhatia S, Arora S, Bhatia SM, et al. Non-ST-segment elevation myocardial infarction among patients with chronic renal disease: a propensity score-matched comparison of percutaneous coronary intervention versus conservative management. J Am Heart Assoc 2018;7:e007920.
Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and renal dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 2016;12:610-23.
Vindhyal MR, Khayyat S, Shaaban A, et al. Decreased renal function is associated with heart failure readmissions. Cureus 2018;10:e3122.
Hein AM, Scialla JJ, Sun JL, et al. Estimated glomerular filtration rate variability in patients with heart failure and chronic renal disease. J Card Fail 2021;27:1175-84.
Banglore S, Maron DJ, O’Brien SM, et al. Management of coronary disease in patients with advanced renal disease. N Engl J Med 2020;382:1395e1407.
Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 2018;379:250-9.
Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Renal Dis 2018;25:382-90.
Kumar U, Wettersten N, Garimella PS. Cardiorenal syndrome: pathophysiology. Cardiol Clin 2019;37:251-65.
Ethics Approval
The study protocol has been approved by the institutional review board. The committee assessed the planned project as ethically unobjectionable.How to Cite
Ji, Bing, Tongqing Yao, Jing Tong, Zi Ye, Fan Ping, Fei Chen, and Xue-Bo Liu. 2023. “Impact of Percutaneous Coronary Intervention on Renal Function in Patients With Coronary Heart Disease”. Monaldi Archives for Chest Disease 94 (4). https://doi.org/10.4081/monaldi.2023.2766.
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
